Lymphoma & CLL Subtypes

Using ctDNA analysis in risk profiling of frontline DLBCL: Results from the POLARIX study

In the risk profiling of previously untreated patients with DLBCL from the POLARIX study using ctDNA, results...

The NEUTRODIET trial: Is a protective diet necessary after SCT?

Here, we summarize new findings from the phase III NEUTRODIET trial. The trial revealed no significant difference in infection rates,...

Zanubrutinib receives FDA approval for CLL and SLL

The U.S. Food and Drug Administration (FDA) has granted approval to zanubrutinib for the treatment of adult patients with chronic lymphocytic...

Zanubrutinib versus ibrutinib in R/R CLL/SLL: final ALPINE results

Final results of the ALPINE trial were presented by Jennifer Brown at the late-breaking abstracts session of #ASH22. Zanubrutinib...

Frontline ibrutinib for younger patients with MCL: Results from the phase III TRIANGLE trial

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, Martin Dreyling...

TARMAC: Can we combine targeted therapy with CAR T-cells in MCL?

During the 64th ASH Annual Meeting and Exposition, the Lymphoma Hub spoke to Adrian Minson, Peter MacCallum Cancer Centre, Melbourne,...

SYMPHONY 1: A trial update

During the 64th ASH Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked for an update on...

Mosunetuzumab receives FDA approval for the treatment of R/R follicular lymphoma

On December 22, 2022, it was announced that mosunetuzumab, a CD20 × CD3 T-cell engaging bispecific antibody, had...